660 related articles for article (PubMed ID: 32103527)
41. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
42. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
Shi X; Li H; Shi A; Yao H; Ke K; Dong C; Zhu Y; Qin Y; Ding Y; He YH; Liu X; Li L; Lei L; Hai Q; Chen W; Leung KS; Wong MH; Kung HF; Lin MC
Oncol Rep; 2018 Sep; 40(3):1592-1600. PubMed ID: 29956794
[TBL] [Abstract][Full Text] [Related]
43. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
44. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
Chen F; Zhang Z; Yu Y; Liu Q; Pu F
Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
[TBL] [Abstract][Full Text] [Related]
45. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
VanArsdale T; Boshoff C; Arndt KT; Abraham RT
Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
[TBL] [Abstract][Full Text] [Related]
46. Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.
Shan H; Ma X; Yan G; Luo M; Zhong X; Lan S; Yang J; Liu Y; Pu C; Tong Y; Li R
Eur J Med Chem; 2021 Jul; 219():113432. PubMed ID: 33857728
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
48. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
49. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
50. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Cao Y; Li X; Kong S; Shang S; Qi Y
J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
[TBL] [Abstract][Full Text] [Related]
51. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
52. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
53. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
54. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
55. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
56. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
57. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Tate SC; Cai S; Ajamie RT; Burke T; Beckmann RP; Chan EM; De Dios A; Wishart GN; Gelbert LM; Cronier DM
Clin Cancer Res; 2014 Jul; 20(14):3763-74. PubMed ID: 24850847
[TBL] [Abstract][Full Text] [Related]
58. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
60. Molecular pathways: CDK4 inhibitors for cancer therapy.
Dickson MA
Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
